T-prolymphocytic leukaemia
Disclosures
- updated 6 Dec 2022:
Nothing to disclose
Updates to Article Attributes
Title
was changed:
T-cell prolymphocytic-prolymphocytic leukaemia
Body
was changed:
T-cell prolymphocytic-prolymphocytic leukaemia (T-PLL) is a rare and unusual haematological malignancy.
Terminology
In the most recent version of the WHO classification, this is referred to as T-prolymphocytic leukaemia rather than T-cell prolymphocytic leukaemia.
Epidemiology
It represents around 2% of all mature lymphocytic leukaemias in adults over the age of 30 1. It usually affects older adults, with an average age at presentation being around 65 years. There may be a slight male predominance.
Clinical presentation
While there can be a potentially-wide clinical spectrum, many patients tend to present with hepatosplenomegaly and generalised lymphadenopathy.
Pathology
It is characterised by the proliferation of small- to medium-sized prolymphocytes of post-thymic origin. ThereMany tissues can be a wide spectrum where involvement of theinvolved, including peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin can occur.
Radiographic features
General
The imaging spectrum can also be variable with hepatosplenomegaly and generalised lymphadenopathy being common. Pleural effusions and cutaneous lesions may also be detectable in a small number of patients.
Treatment and prognosis
Clinical course is often very aggressive with poor response to conventional chemotherapy. Poor survival rates have usually been reported with the potential long-term curative treatment being haematopoietic stem cell transplantation. Treatment with purine analogues and alemtuzumab have been reported to have significantly higher response rates and improved survival 2,3.
See also
-<p><strong>T-cell prolymphocytic leukaemia (T-PLL)</strong> is a rare and unusual haematological malignancy.</p><h4>Epidemiology</h4><p>It represents around 2% of all mature lymphocytic leukaemias in adults over the age of 30 <sup>1</sup>. It usually affects older adults with an average age at presentation being around 65 years. There may be a slight male predominance.</p><h4>Clinical presentation </h4><p>While there can be a potentially-wide clinical spectrum, many patients tend to present with hepatosplenomegaly and generalised lymphadenopathy.</p><h4>Pathology</h4><p>It is characterised by the proliferation of small- to medium-sized prolymphocytes of post-thymic origin. There can be a wide spectrum where involvement of the peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin can occur.</p><h4>Radiographic features</h4><h5>General </h5><p>The imaging spectrum can also be variable with hepatosplenomegaly and generalised lymphadenopathy being common. Pleural effusions and cutaneous lesions may also be detectable in a small number of patients.</p><h4>Treatment and prognosis</h4><p>Clinical course is often very aggressive with poor response to conventional chemotherapy. Poor survival rates have usually been reported with the potential long-term curative treatment being haematopoietic stem cell transplantation. Treatment with purine analogues and alemtuzumab have been reported to have significantly higher response rates and improved survival<sup> 2,3</sup>.</p><h4>See also</h4><ul><li><a href="/articles/2008-who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues">WHO classification of tumours of haematopoietic and lymphoid tissues</a></li></ul>- +<p><strong>T-prolymphocytic leukaemia (T-PLL)</strong> is a rare and unusual haematological malignancy.</p><h4>Terminology</h4><p>In the most recent version of the WHO classification, this is referred to as <strong>T-prolymphocytic leukaemia</strong> rather than <strong>T-cell prolymphocytic leukaemia</strong>.</p><h4>Epidemiology</h4><p>It represents around 2% of all mature lymphocytic leukaemias in adults over the age of 30 <sup>1</sup>. It usually affects older adults, with an average age at presentation being around 65 years. There may be a slight male predominance.</p><h4>Clinical presentation </h4><p>While there can be a potentially-wide clinical spectrum, many patients tend to present with hepatosplenomegaly and generalised lymphadenopathy.</p><h4>Pathology</h4><p>It is characterised by the proliferation of small- to medium-sized prolymphocytes of post-thymic origin. Many tissues can be involved, including peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin.</p><h4>Radiographic features</h4><h5>General </h5><p>The imaging spectrum can also be variable with hepatosplenomegaly and generalised lymphadenopathy being common. Pleural effusions and cutaneous lesions may also be detectable in a small number of patients.</p><h4>Treatment and prognosis</h4><p>Clinical course is often very aggressive with poor response to conventional chemotherapy. Poor survival rates have usually been reported with the potential long-term curative treatment being haematopoietic stem cell transplantation. Treatment with purine analogues and alemtuzumab have been reported to have significantly higher response rates and improved survival<sup> 2,3</sup>.</p><h4>See also</h4><ul><li><p><a href="/articles/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-1">WHO classification of tumours of haematopoietic and lymphoid tissues</a></p></li></ul>
References changed:
- 1. Graham R, Cooper B, Krause J. T-Cell Prolymphocytic Leukemia. Proc (Bayl Univ Med Cent). 2013;26(1):19-21. <a href="https://doi.org/10.1080/08998280.2013.11928902">doi:10.1080/08998280.2013.11928902</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/23382603">Pubmed</a>
- 2. Dearden C. T-Cell Prolymphocytic Leukemia. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S239-43. <a href="https://doi.org/10.3816/CLM.2009.s.018">doi:10.3816/CLM.2009.s.018</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/19778847">Pubmed</a>
- 3. Khot A & Dearden C. T-Cell Prolymphocytic Leukemia. Expert Rev Anticancer Ther. 2009;9(3):365-71. <a href="https://doi.org/10.1586/14737140.9.3.365">doi:10.1586/14737140.9.3.365</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/19275513">Pubmed</a>
- 4. Adelson R, Samy R, Lindberg G. T-Cell Prolymphocytic Leukemia Presenting as an Ear Canal Mass. Otol Neurotol. 2004;25(6):1006-8. <a href="https://doi.org/10.1097/00129492-200411000-00024">doi:10.1097/00129492-200411000-00024</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15547434">Pubmed</a>
- 5. Matutes E, Garcia Talavera J, O'Brien M, Catovsky D. The Morphological Spectrum of T-Prolymphocytic Leukaemia. Br J Haematol. 1986;64(1):111-24. <a href="https://doi.org/10.1111/j.1365-2141.1986.tb07579.x">doi:10.1111/j.1365-2141.1986.tb07579.x</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/3489482">Pubmed</a>
- 1. Graham RL, Cooper B, Krause JR. T-cell prolymphocytic leukemia. Proc (Bayl Univ Med Cent). 2013;26 (1): 19-21. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523759">Free text at pubmed</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/23382603">Pubmed citation</a><span class="auto"></span>
- 2. Dearden CE. T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma. 2009;9 Suppl 3: S239-43. <a href="http://dx.doi.org/10.3816/CLM.2009.s.018">doi:10.3816/CLM.2009.s.018</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/19778847">Pubmed citation</a><span class="auto"></span>
- 3. Khot A, Dearden C. T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther. 2014;9 (3): 365-71. <a href="http://dx.doi.org/10.1586/14737140.9.3.365">doi:10.1586/14737140.9.3.365</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/19275513">Pubmed citation</a><span class="auto"></span>
- 4. Adelson RT, Samy RN, Lindberg G. T-cell prolymphocytic leukemia presenting as an ear canal mass. Otol. Neurotol. 2005;25 (6): 1006-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15547434">Pubmed citation</a><span class="auto"></span>
- 5. Matutes E, Garcia Talavera J, O'Brien M et-al. The morphological spectrum of T-prolymphocytic leukaemia. Br. J. Haematol. 1986;64 (1): 111-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3489482">Pubmed citation</a><span class="auto"></span>
Updates to Synonym Attributes
Title
was added:
T-cell prolymphocytic leukemia
Slug
was set to
t-cell-prolymphocytic-leukemia-1.
Type
was set to
Synonym.
Visible
was set to
.
Content Type
was set to
Article.
Updates to Link Attributes
Title
was removed:
Type
was removed.
Visible
was set to
.
Updates to Primarylink Attributes
Title
was added:
T-prolymphocytic leukaemia
Slug
was set to
t-prolymphocytic-leukaemia.
Type
was set to
PrimaryLink.
Visible
was set to
.
Content
was set to
.
Content Type
was set to
Article.
Unable to process the form. Check for errors and try again.